Drug intelligence / Profile preview

LL-BMT1

Development stage: Unknown
Lead developer: MediPrint Ophthalmics
Modality: Small Molecules
Administration: Ophthalmic

Overview

**LL-BMT1** is a preservative-free, drug-eluting contact lens developed by MediPrint Ophthalmics for weekly ophthalmic treatment of primary open-angle glaucoma and ocular hypertension. The lens is designed to continuously release the prostamide bimatoprost during wear, including overnight, to lower elevated intraocular pressure and reduce dependence on daily topical eye drops. The product is a drug-device combination formulation intended to improve treatment adherence, reduce intraocular-pressure fluctuation, and provide sustained ocular drug exposure.

Targets

PTGFR (Prostaglandin F2 alpha receptor)

Beyond the preview

Go deeper on LL-BMT1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LL-BMT1.

Explore the full profile